102 related articles for article (PubMed ID: 11361794)
1. ACTG 315 drug cocktail restores immune function.
AIDS Patient Care STDS; 1997 Jun; 11(3):193. PubMed ID: 11361794
[No Abstract] [Full Text] [Related]
2. Undetectable HIV levels after triple therapy with indinavir.
AIDS Patient Care STDS; 1997 Jun; 11(3):193-4. PubMed ID: 11361795
[No Abstract] [Full Text] [Related]
3. ACTG 320 trial halted as three-drug arm proves superior.
AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361796
[No Abstract] [Full Text] [Related]
4. [Experiences with antiretroviral combination therapy].
Justesen US; Mygind LH; Pedersen SS; Pedersen C
Ugeskr Laeger; 1999 Mar; 161(12):1747-51. PubMed ID: 10210973
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
7. ICAAC update.
Coppedge B
STEP Perspect; 1996; 8(3):15-6. PubMed ID: 11364265
[TBL] [Abstract][Full Text] [Related]
8. Lower dose maintenance therapy?
Proj Inf Perspect; 1998 Apr; (24):9. PubMed ID: 11365720
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitor combination.
AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361664
[No Abstract] [Full Text] [Related]
10. Spring cleaning in trial land.
Gilden D
GMHC Treat Issues; 1997 Mar; 11(3):4-7. PubMed ID: 11364275
[TBL] [Abstract][Full Text] [Related]
11. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head study of protease inhibitors.
AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
[No Abstract] [Full Text] [Related]
13. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
15. Sustiva added to three-drug combination.
AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030
[No Abstract] [Full Text] [Related]
16. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
17. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
18. ACTG 320: last of the body count trials?
PI Perspect; 1997 Mar; (No 21):7. PubMed ID: 11364215
[TBL] [Abstract][Full Text] [Related]
19. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
20. Phase II/III Trials of Viracept start.
AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
